PUBLISHER: Grand View Research | PRODUCT CODE: 1813887
PUBLISHER: Grand View Research | PRODUCT CODE: 1813887
The global transaminase test market size was estimated at USD 4.10 billion in 2024 and is projected to reach USD 7.81 billion by 2033, growing at a CAGR of 7.54% from 2025 to 2033. This market centers on rapid, accurate diagnostic platforms, such as AST (Aspartate Transaminase) and GOT (Glutamic Oxaloacetic Transaminase) assays, used extensively in liver function assessment, disease monitoring, and general health screening.
These platforms support timely clinical decisions, driven by increasing awareness of liver diseases and widespread integration into hospital, clinical, and point-of-care settings. The growth in the transaminase test industry is propelled by a combination of advancing technology and increasing access in emerging markets. Innovations in point-of-care AST/GOT devices-bolstered by AI-enabled interpretation-are reducing turnaround times and improving precision. Accessibility is expanding beyond well-resourced labs to outpatient clinics and rural settings, thanks to portable formats and software-driven automation.
Another major growth driver is the rising global burden of liver disease. The increasing prevalence of non-alcoholic fatty liver disease (NAFLD), viral hepatitis, and alcohol-related liver conditions underscores the need for regular transaminase screening. Coupled with aging populations and preventive health programs, demand is mounting for reliable, cost-effective liver biomarker tests.
In March 2025, the European Medicines Agency (EMA) approved the use of the artificial intelligence (AI) tool AIM-NASH in clinical trials to assess the severity of metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease. Developed using machine learning, AIM-NASH was trained with over 100,000 annotations from 59 pathologists and evaluated more than 5,000 liver biopsies across nine large clinical trials. The EMA's human medicines committee confirmed that AIM-NASH can reliably determine disease activity from biopsies with less variability than the current standard, which typically relies on a consensus of three pathologists. This advancement is expected to enhance the clarity of evidence regarding the benefits of new treatments in clinical trials.
Overall, the global transaminase test market is experiencing significant transformation, driven by technological advancements and evolving healthcare needs. Integrating artificial intelligence (AI) into diagnostic platforms enhances the precision and efficiency of liver function assessments, enabling earlier detection and personalized treatment strategies. Point-of-care testing (POCT) expands access to liver diagnostics, particularly in remote and underserved regions, by providing rapid and convenient testing options. Furthermore, developing non-invasive diagnostic tools reduces reliance on traditional biopsy procedures, aligning with the growing preference for less invasive methods among patients and healthcare providers.
These innovations are improving patient outcomes and reshaping the competitive landscape, prompting key players to invest in research and development to stay at the forefront of the market. With the demand for efficient and accessible liver diagnostics continuing to rise, the market is well-positioned for sustained growth, offering opportunities for companies to leverage emerging technologies and meet the evolving needs of the global healthcare ecosystem.
Global Transaminase Test Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the transaminase test market on the basis of test type, technology, application, end use, and region: